Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality [Seeking Alpha]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Seeking Alpha
VNDA's aggressive investment in commercial infrastructure has driven 31% Fanapt sales growth, but resulted in higher cash burn and quarterly losses. Key regulatory catalysts loom with PDUFA dates for Bysanti and tradipitant, and tradipitant's GLP-1 adjunct potential offers significant upside. Risks include ongoing cash burn, regulatory uncertainty, and competition, but VNDA's balance sheet supports its strategy through upcoming milestones. Jonathan Kitchen/DigitalVision via Getty Images Vanda Pharmaceuticals ( VNDA ) is at a special juncture of the commercial development of existing products, and the potential for major regulatory milestones. My search for a Biotech opportunity that has the largest asymmetric risk vs This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness [Yahoo! Finance]Yahoo! Finance
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion SicknessPR Newswire
- Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VNDA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
- Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness [Yahoo! Finance]Yahoo! Finance
VNDA
Earnings
- 10/29/25 - Miss
VNDA
Sec Filings
- 12/4/25 - Form 8-K
- 11/28/25 - Form 8-K
- 10/30/25 - Form 10-Q
- VNDA's page on the SEC website